Reference | 1: Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John
T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z,
Yang JC. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer
with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and
dose-expansion study. Lancet Respir Med. 2017 Nov;5(11):891-902. doi:
10.1016/S2213-2600(17)30378-8. Epub 2017 Oct 19. PubMed PMID: 29056570.
<br>
2: Planchard D. AZD3759 for CNS metastases in EGFR-mutant lung cancer. Lancet
Respir Med. 2017 Nov;5(11):841-842. doi: 10.1016/S2213-2600(17)30395-8. Epub 2017
Oct 19. PubMed PMID: 29056569.
<br>
3: Xiong S, Xue M, Mu Y, Deng Z, Sun P, Zhou R. Determination of AZD3759 in rat
plasma and brain tissue by LC-MS/MS and its application in pharmacokinetic and
brain distribution studies. J Pharm Biomed Anal. 2017 Jun 5;140:362-366. doi:
10.1016/j.jpba.2017.03.056. Epub 2017 Mar 31. PubMed PMID: 28399431.
<br>
4: Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S,
Kim DW, Ahn MJ, Yang JC, Zhang X. AZD3759, a BBB-penetrating EGFR inhibitor for
the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016 Dec
7;8(368):368ra172. PubMed PMID: 27928026.
<br>
5: Zeng Q, Wang J, Cheng Z, Chen K, Johnström P, Varnäs K, Li DY, Yang ZF, Zhang
X. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active,
Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine
Kinase Inhibitor. J Med Chem. 2015 Oct 22;58(20):8200-15. doi:
10.1021/acs.jmedchem.5b01073. Epub 2015 Oct 9. PubMed PMID: 26313252.
|